AU2020346898B2 - Phospholipid ether conjugates as cancer-targeting drug vehicles - Google Patents

Phospholipid ether conjugates as cancer-targeting drug vehicles

Info

Publication number
AU2020346898B2
AU2020346898B2 AU2020346898A AU2020346898A AU2020346898B2 AU 2020346898 B2 AU2020346898 B2 AU 2020346898B2 AU 2020346898 A AU2020346898 A AU 2020346898A AU 2020346898 A AU2020346898 A AU 2020346898A AU 2020346898 B2 AU2020346898 B2 AU 2020346898B2
Authority
AU
Australia
Prior art keywords
cancer
compound
pharmaceutically acceptable
melanoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020346898A
Other languages
English (en)
Other versions
AU2020346898A1 (en
Inventor
Randall HOOVER
Zhongping Huang
Jarrod LONGCOR
Anatoly Pinchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectar Biosciences Inc
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of AU2020346898A1 publication Critical patent/AU2020346898A1/en
Application granted granted Critical
Publication of AU2020346898B2 publication Critical patent/AU2020346898B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2020346898A 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles Active AU2020346898B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962899611P 2019-09-12 2019-09-12
US201962899618P 2019-09-12 2019-09-12
US201962899615P 2019-09-12 2019-09-12
US62/899,615 2019-09-12
US62/899,611 2019-09-12
US62/899,618 2019-09-12
US201962946870P 2019-12-11 2019-12-11
US62/946,870 2019-12-11
US202062956844P 2020-01-03 2020-01-03
US202062956907P 2020-01-03 2020-01-03
US62/956,844 2020-01-03
US62/956,907 2020-01-03
PCT/US2020/050459 WO2021050917A1 (en) 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles

Publications (2)

Publication Number Publication Date
AU2020346898A1 AU2020346898A1 (en) 2022-04-07
AU2020346898B2 true AU2020346898B2 (en) 2026-04-09

Family

ID=74866023

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020346898A Active AU2020346898B2 (en) 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles

Country Status (12)

Country Link
US (1) US20230066517A1 (https=)
EP (1) EP4028018A4 (https=)
JP (3) JP7749542B2 (https=)
KR (1) KR20220062363A (https=)
CN (1) CN114599371A (https=)
AU (1) AU2020346898B2 (https=)
BR (1) BR112022004482A2 (https=)
CA (1) CA3150991A1 (https=)
IL (1) IL291197A (https=)
MX (1) MX2022003044A (https=)
NZ (1) NZ786360A (https=)
WO (1) WO2021050917A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095515A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
NZ786360A (en) * 2019-09-12 2025-12-19 Cellectar Biosciences Inc Phospholipid ether conjugates as cancer-targeting drug vehicles
BR112022006739B1 (pt) * 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
CN113816990B (zh) * 2021-03-22 2023-08-22 联宁（苏州）生物制药有限公司 修饰的氨基酸及其在adc中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160136190A1 (en) * 2014-11-17 2016-05-19 Cellectar Biosciences, Inc. Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) * 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
WO2011031919A2 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
WO2017218702A1 (en) * 2016-06-14 2017-12-21 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
CA3095515A1 (en) 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
NZ786360A (en) * 2019-09-12 2025-12-19 Cellectar Biosciences Inc Phospholipid ether conjugates as cancer-targeting drug vehicles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160136190A1 (en) * 2014-11-17 2016-05-19 Cellectar Biosciences, Inc. Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles

Also Published As

Publication number Publication date
MX2022003044A (es) 2022-06-02
WO2021050917A1 (en) 2021-03-18
NZ786360A (en) 2025-12-19
EP4028018A4 (en) 2023-10-11
CN114599371A (zh) 2022-06-07
JP7749542B2 (ja) 2025-10-06
KR20220062363A (ko) 2022-05-16
JP2025138792A (ja) 2025-09-25
IL291197A (en) 2022-05-01
JP2022547331A (ja) 2022-11-11
AU2020346898A1 (en) 2022-04-07
BR112022004482A2 (pt) 2022-05-31
JP2025087716A (ja) 2025-06-10
EP4028018A1 (en) 2022-07-20
CA3150991A1 (en) 2021-03-18
US20230066517A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US11439709B2 (en) Phospholipid ether analogs as cancer-targeting drug vehicles
AU2020346898B2 (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
JP6592097B2 (ja) 併用療法
US12496346B2 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
EP2890374B1 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
EA053296B1 (ru) Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак
HK40075720A (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
HK40042533A (en) Phospholipid ether analogs as cancer-targeting drug vehicles
CN117769416A (zh) Bak激活剂、药物组合物和在治疗癌症中的用途
NZ731669B2 (en) Phospholipid ether analogs as cancer-targeting drug vehicles